Clinical Trials Directory

Trials / Completed

CompletedNCT00595907

Results of an Interferon-Gamma Release Assay After Treatment for Tuberculosis

Observational Study of Production of IFN-Gamma by Peripheral Lymphocytes in Response to Specific Antigens Before and After Treatment for Tuberculosis

Status
Completed
Phase
Study type
Observational
Enrollment
89 (actual)
Sponsor
University Hospital, Geneva · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

New blood tests have become available to detect either latent or active tuberculosis. These tests - which according to the CDC can replace the tuberculin skin test - measure the production of gamma-interferon (a cytokine) by peripheral lymphocytes (white cells) when exposed to antigens which are highly specific of mycobacterium tuberculosis (the bacteria responsible for tuberculosis). Our hypothesis was that the production of gamma-interferon would be much higher at the beginning of treatment than at the end, and that decline in gamma-interferon secretion could be an indicator of clinical response to treatment.

Detailed description

Patients either treated for active culture proven tuberculosis (TB) or having completed treatment during the preceding 6 months were recruited. Exclusion criteria were : HIV infection and previous TB. Interferon gamma release assay (T-SPOT.TB, Oxford Immunotec) was sampled during the 2 first weeks of treatment, at the end of treatment and 6 months later. T-SPOT.TB was analysed qualitatively (pos/neg) and quantitatively (Spot forming units: SFU) to determine if there was a higher rate of negative tests at the end of treatment and 6 months after treatment than initially. Paired samples were analysed to compare SFU counts between beginning of treatment and end of treatment, and SFU counts between end of treatment and 6 months later. Clinical response to treatment was recorded, as well as treatment failures and relapses.

Conditions

Timeline

Start date
2004-10-01
Primary completion
2006-07-01
Completion
2006-07-01
First posted
2008-01-16
Last updated
2008-01-16

Locations

1 site across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT00595907. Inclusion in this directory is not an endorsement.